India Pharma Outlook Team | Friday, 17 July 2026
Merck’s cholesterol pill is poised to reshape the global cardiovascular drug landscape. This comes with the latest approval from the U.S. Food and Drug Administration for its first-in-class oral PCSK9 inhibitor.
The approval marks a significant turning point in the treatment of high cholesterol, traditionally dominated by injectable biologics.
Beyond its clinical promise, the drug signals a major strategic shift for Merck & Co. As it seeks to diversify revenue streams and reduce reliance on its cancer therapy, Keytruda.
With analysts projecting peak annual sales of up to USD 5 billion, the launch is expected to trigger intense competition in the lipid-lowering therapy market.
The competition from Merck's new drug for the PCSK9 market is a game-changer for existing injectable treatments like Amgen's Repatha and Praluent of Regeneron Pharmaceuticals.
These drugs have dominated the market but are limited by their injectable format. Merck’s oral therapy changes that equation by offering a more convenient, patient-friendly option without compromising efficacy.
Clinical data indicates that the drug significantly reduces low-density lipoprotein (LDL) cholesterol levels, positioning it as a strong competitor in a space where innovation has been incremental rather than transformative.
Key competitive advantages include:
This shift could expand the eligible patient pool and accelerate adoption, particularly among individuals reluctant to opt for injectable treatments.
Also Read: Scaling Perfusion Technology from Lab Success to Manufacturing Reality
For Merck, the approval is not just about entering a new therapeutic category. Rather, it is a critical step in reshaping its long-term business strategy. The company has been heavily reliant on Keytruda, which accounts for a substantial portion of its revenue. As patent expirations loom in the coming years, the need to build a diversified portfolio has become increasingly urgent.
The new cholesterol therapy represents one of the most promising candidates to offset this dependency. By tapping into the vast cardiovascular Merck is positioning itself for sustained growth beyond oncology.
Strategically, the move also aligns with broader industry trends:
This dual focus on innovation and accessibility strengthens Merck’s competitive standing against peers who are also racing to broaden their pipelines.
The global cholesterol-lowering drug market is valued in the billions, driven by the rising prevalence of cardiovascular diseases worldwide. High cholesterol remains a leading risk factor for heart attacks and strokes, underscoring the demand for effective and scalable treatment options.
Merck’s oral PCSK9 inhibitor is expected to play a pivotal role in this evolving landscape. Analysts estimate peak sales could reach USD 5 billion annually, reflecting strong commercial potential.
However, success will depend on several factors, including pricing strategies, physician adoption, and real-world patient outcomes. The broader implications for the pharmaceutical industry are equally significant.
The approval demonstrates that complex biologic mechanisms can be successfully translated into oral formulations, opening the door for similar innovations across therapeutic areas.
As competition intensifies, the introduction of an oral alternative could redefine treatment paradigms and force existing players to adapt. For patients, it promises greater convenience and potentially improved adherence in managing chronic conditions effectively.
